ヒト上皮成長因子受容体2陰性乳がん（HER2乳がん）-世界の臨床試験レビュー：2024年

当レポートでは、ヒト上皮成長因子受容体2陰性乳がん（HER2乳がん）の臨床試験市場について調査し、市場の概要とともに、試験フェーズ別、試験状況別、試験回数別、エンドポイントステータス別、スポンサータイプ別、主要国別動向、主要企業、臨床試験プロファイルなどを提供しています。

目次

• レポートガイダンス
• 臨床試験調査範囲
• 地域別臨床試験
• 国別臨床試験と平均登録者数
• アジア太平洋において臨床試験に貢献する主要5カ国
• 欧州において臨床試験に貢献する主要5カ国
• 北米において臨床試験に貢献する主要5カ国
• 中東・アフリカにおいて臨床試験に貢献する主要5カ国
• 中南米において臨床試験に貢献する主要5カ国
• G7諸国別臨床試験：ヒト上皮成長因子受容体2陰性乳がん（HER2乳がん）の腫瘍学臨床試験に対する割合
• G7諸国における臨床試験、フェーズ別
• G7諸国における臨床試験、試験状況別
• E7諸国別臨床試験：ヒト上皮成長因子受容体2陰性乳がん（HER2乳がん）の腫瘍学臨床試験に対する割合
• E7諸国における臨床試験、フェーズ別
• E7諸国における臨床試験、試験状況別
• 臨床試験、フェーズ別
• 進行中試験、フェーズ別
• 臨床試験、試験状況別
• 臨床試験、エンドポイントステータス別
• 一定期間にわたって採用された被験者
• 臨床試験、スポンサータイプ別
• 著名なスポンサー
• ヒト上皮成長因子受容体2陰性乳がん（HER2乳がん）治療薬の臨床試験に参加している主要企業
• 主要な薬剤
• 臨床試験プロファイルの概要

付録

• 略語
• 定義
• 調査手法
• 2次調査
• GlobalDataについて
• お問い合わせ
• 情報源

List of Tables

• Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics, Global, Clinical Trials by Region, 2024*
• Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2024*
• Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2024*
• Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2024*
• Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics Clinical Trials, Europe, Top Five Countries, 2024*
• Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics Clinical Trials, North America, Top Countries, 2024*
• Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2024*
• Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2024*
• Proportion of Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) to Oncology Clinical Trials, G7 Countries (%), 2024*
• Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics, G7 Countries, Clinical Trials by Phase, 2024*
• Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2024*
• Proportion of Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) to Oncology Clinical Trials, E7 Countries (%), 2024*
• Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics, E7 Countries, Clinical Trials by Phase, 2024*
• Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2024*
• Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics, Global, Clinical Trials by Phase, 2024*
• Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics, Global, Clinical Trials In Progress by Phase 2024*
• Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics, Global, Clinical Trials by Trial Status, 2024*
• Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics Clinical Trials, Global, by End Point Status, 2024*
• Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2019-2023
• Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2024*
• Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics Clinical Trials, Global, Key Sponsors, 2024*
• Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2024*
• Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2024*

List of Figures

• Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics, Global, Clinical Trials by Region (%), 2024*
• Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2024*
• Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2024*
• Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2024*
• Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2024*
• Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics Clinical Trials, North America, Top Countries (%), 2024*
• Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2024*
• Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2024*
• Proportion of Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) to Oncology Clinical Trials, G7 Countries (%), 2024*
• Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics, G7 Countries, Clinical Trials by Phase, 2024*
• Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2024*
• Proportion of Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) to Oncology Clinical Trials, E7 Countries (%), 2024*
• Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics, E7 Countries, Clinical Trials by Phase, 2024*
• Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2024*
• Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics, Global, Clinical Trials by Phase (%), 2024*
• Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics, Global, Clinical Trials In Progress by Phase, 2024*
• Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics, Global, Clinical Trials by Trial Status, 2024*
• Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics Clinical Trials, Global, by End Point Status, 2024*
• Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2019-2023
• Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2024*
• Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics Clinical Trials, Global, Key Sponsors, 2024*
• Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2024*
• Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2024*
• GlobalData Methodology

GlobalData's clinical trial report, "Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) - Global Clinical Trials Review, 2024" provides an overview of Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Clinical trials scenario. This report provides top line data relating to the clinical trials on Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma - Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

• The report provides a snapshot of the global clinical trials landscape
• Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
• The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
• The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
• The Report provides enrollment trends for the past five years
• Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to Buy

Assists in formulating key business strategies with regards to investment

Helps in identifying prominent locations for conducting clinical trials which saves time and cost

Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

Supports understanding of trials count and enrollment trends by country in global therapeutics market

Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

• Report Guidance
• GlobalData Clinical Trials Report Coverage
• Clinical Trials by Region
• Clinical Trials and Average Enrollment by Country
• Top Five Countries Contributing to Clinical Trials in Asia-Pacific
• Top Five Countries Contributing to Clinical Trials in Europe
• Top Countries Contributing to Clinical Trials in North America
• Top Five Countries Contributing to Clinical Trials in Middle East and Africa
• Top Five Countries Contributing to Clinical Trials in Central and South America
• Clinical Trials by G7 Countries: Proportion of Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) to Oncology Clinical Trials
• Clinical Trials by Phase in G7 Countries
• Clinical Trials in G7 Countries by Trial Status
• Clinical Trials by E7 Countries: Proportion of Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) to Oncology Clinical Trials
• Clinical Trials by Phase in E7 Countries
• Clinical Trials in E7 Countries by Trial Status
• Clinical Trials by Phase
• In Progress Trials by Phase
• Clinical Trials by Trial Status
• Clinical Trials by End Point Status
• Subjects Recruited Over a Period of Time
• Clinical Trials by Sponsor Type
• Prominent Sponsors
• Top Companies Participating in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics Clinical Trials
• Prominent Drugs
• Clinical Trial Profile Snapshots
• Abbreviations
• Definitions
• Research Methodology
• Secondary Research
• About GlobalData
• Contact Us
• Disclaimer
• Source